Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The effects of brain AngII (angiotensin II) depend on AT1 receptor (AngII type 1 receptor) stimulation and include regulation of cerebrovascular flow, autonomic and hormonal systems, stress, innate immune response and behaviour. Excessive brain AT1 receptor activity associates with hypertension and heart failure, brain ischaemia, abnormal stress responses, blood–brain barrier breakdown and inflammation. These are risk factors leading to neuronal injury, the incidence and progression of neurodegerative, mood and traumatic brain disorders, and cognitive decline. In rodents, ARBs (AT1 receptor blockers) ameliorate stress-induced disorders, anxiety and depression, protect cerebral blood flow during stroke, decrease brain inflammation and amyloid-β neurotoxicity and reduce traumatic brain injury. Direct anti-inflammatory protective effects, demonstrated in cultured microglia, cerebrovascular endothelial cells, neurons and human circulating monocytes, may result not only in AT1 receptor blockade, but also from PPARγ (peroxisome-proliferator-activated receptor γ) stimulation. Controlled clinical studies indicate that ARBs protect cognition after stroke and during aging, and cohort analyses reveal that these compounds significantly reduce the incidence and progression of Alzheimer's disease. ARBs are commonly used for the therapy of hypertension, diabetes and stroke, but have not been studied in the context of neurodegenerative, mood or traumatic brain disorders, conditions lacking effective therapy. These compounds are well-tolerated pleiotropic neuroprotective agents with additional beneficial cardiovascular and metabolic profiles, and their use in central nervous system disorders offers a novel therapeutic approach of immediate translational value. ARBs should be tested for the prevention and therapy of neurodegenerative disorders, in particular Alzheimer's disease, affective disorders, such as co-morbid cardiovascular disease and depression, and traumatic brain injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“Clinical studies—Numerous large controlled clinical studies have concluded that ARBs may be considered the drugs of choice in stroke prevention and post-stroke chronic care, and there are indications that ARBs prevent cognition decline more effectively than other antihypertensive medications [5,157–169] (Table 1).”
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Both thiazolidones have been reported to improve cognition in these patients [257]; however, rosiglitazone penetrates the brain poorly and is associated with risk of myocardial infarction and death [258,259].”
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924 · cited 1×
“Furthermore, stimulation of AT1 receptors by AngII and of TLR4 by LPS use similar proinflammatory mechanisms of signal transduction, including activation of NF-κB, AP-1, iNOS, COX-2 and NADPH oxidase and excessive ROS generation, leading to activation of microglia and further inflammatory cascades [32,45,110,111] (Fig…”
McEwen, B. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.071 · Cited by 1,864 · cited 5×
“There is a concomitant central and peripheral sympathetic activation, involvement of multiple and widespread sensory receptive and motor components, and major behavioural changes [23,56,57].”
Influential'Vascular Depression' Hypothesis
Alexopoulos, G. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220033006 · Cited by 1,843 · cited 1×
“The co-morbidity between mood disorders, and in particular major depression, dysfunctional responses to stress, neurodegenerative disorders and cardiovascular disease, has been wellestablished [10,58,199–203].”
Cited by
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Brain inflammation and hypertension: the chicken or the egg?
Winklewski, P. J., Radkowski, M., Wszedybyl-Winklewska, M., & Demkow, U. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0306-8 · Cited by 116
Angiotensin type 1 receptor inhibition enhances the extinction of fear memory
Marvar, P. J., Goodman, J., Fuchs, S., Choi, D. C., Banerjee, S., & Ressler, K. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.024 · Cited by 110
de Kloet, A. D., Liu, M., Rodríguez, V., Krause, E. G., & Sumners, C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00078.2015 · Cited by 64
“Furthermore, accumulating evidence has indicated that the beneficial properties of RAS blockade are attributable, in part, to anti-inflammatory actions (11, 155).”
BackgroundThe role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)
Vadhan, J. D., & Speth, R. C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107684 · Cited by 42
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Saavedra, J. M. (2021) · Physiology · doi:10.1152/physiol.00036.2020 · Cited by 37
Self-citationDerington, C. G., Berchie, R. O., Scharfstein, D. O., Andrews, R. M., Greene, T. H., Xu, Y., King, J. B., Supiano, M. A., Sonnen, J. A., Williamson, J., et al. (2025) · The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glaf028 · Cited by 8
“…Vol. 80, No. 7 dementia due to their direct antagonism of angiotensin type (AT) 1 receptor, thereby shifting circulating angiotensin-II to bind and activate AT2 and AT4 receptors, reducing oxidative stress, neuroinflammation, and endothelial dysfunction while improving cerebral hypoperfusion (2,3).”
Metadata
- Authors
- Saavedra, J. M.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2012-07-23
- Volume
- 123
- Issue
- 10
- Pages
- 567-590
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2002192631
- Cited by
- 217
- References
- 39
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.